Contraception Morocco 2026: pill, IUD, implant prices + reimbursement

01Contraception in Morocco in figures#

Morocco is among the pioneering countries of the Arab and African world in family planning. The National Family Planning Programme (PNPF), launched as early as 1966 at the initiative of the Ministry of Health, with UNFPA support from 1975, has transformed the country's demographic landscape in just a few decades. Where the total fertility rate exceeded 7 children per woman in the 1960s, it fell to 1.97 children per woman in the High Commission for Planning's 2024 census, below the generational replacement threshold (2.1).

This demographic transition largely rests on the spread of contraception. According to the National Survey on Population and Family Health (ENPSF) 2018, 71% of married women of childbearing age currently use a contraceptive method, and 58% of all married women use a so-called "modern" method (pill, IUD, implant, injection, condom, sterilisation). This prevalence places Morocco among the leading countries of the Arab world in family planning, ahead of most neighbouring countries. The pill remains by far the most used method, taken by 48.7% of married women (over two thirds of contraceptive users), followed by the IUD (4.6%), the condom (2.5%) and the implant whose share is rapidly progressing.

Several disparities however persist and deserve to be known. Contraceptive coverage is only slightly lower in rural areas (70.3%) than in urban areas (71.1%), and among less-educated or non-educated women. Adolescents and young unmarried women historically have more difficult access to contraception, due to cultural barriers and sometimes reluctance from some professionals — but things are evolving and more and more gynaecologists accept these consultations in private practice. Access to emergency contraception remains irregular across the territory, although it is sold in pharmacies (listed in schedule A, it requires a prescription in principle).

02Contraceptive methods and their effectiveness#

The choice of a contraceptive method is eminently personal and depends on several factors: age, parity (having had children or not), hormonal tolerance, sex life, desire for short or long-term pregnancy, medical contraindications, family and religious context. A good professional never proposes a single method but presents the range of options helping the woman identify the one that suits her best. Contraceptive effectiveness is measured by the Pearl Index, which corresponds to the number of unwanted pregnancies per 100 women using the method for a year. The lower the index, the more effective the method.

The gap between perfect use and typical use is particularly telling for the pill: technically very effective (99.7%), it loses 8 to 9 points in real-world use due to missed doses. This is why so-called "long-acting reversible" (LARC: implant, IUD) methods are now considered by WHO as the most reliable as they do not depend on daily compliance — once placed, they ensure effective contraception for several years without any action from the woman.

03The pill: combined or progestin-only#

The contraceptive pill exists in two main categories with different indications and precautions, which it is essential to distinguish properly.

The combined oestrogen-progestin pill combines an oestrogen (generally ethinylestradiol) and a progestin. It blocks ovulation through hypothalamic feedback, modifies cervical mucus and the endometrium. Beyond its contraceptive role, it brings several non-contraceptive benefits: regularisation of menstrual cycles, reduction of menstrual flow and therefore of iron-deficiency anaemia, favourable action on acne and hirsutism, reduction of dysmenorrhoea, protection against functional ovarian cysts and against certain pathologies (ovarian cancer, endometrial cancer). This pill is however contraindicated in several situations that any prescriber must carefully verify: smoking after 35 (thromboembolic risk multiplied by 5 to 15), uncontrolled arterial hypertension, migraines with aura (stroke risk), personal or family history of deep vein thrombosis or pulmonary embolism, active or recent breast cancer, significant cardiovascular diseases, complicated diabetes.

The progestin-only pill, which contains only a progestin without oestrogen (desogestrel for example), is a precious alternative for women unable to take combined pills. It is compatible with breastfeeding (oestrogen decreases lactation, progestin alone does not), with smoking, with moderate hypertension or migraine history. Its main constraint is very rigorous intake: for levonorgestrel, the missed-dose tolerance window is only 3 hours (compared to 12 hours for the combined pill and some modern progestins like desogestrel). A delay beyond this window requires condom use for 7 days and possibly emergency contraception if intercourse occurred in the 5 preceding days.

In case of missed pill, the rules to know are simple but crucial. For the combined pill, a missed dose of less than 12 hours generally has no consequence: just take the missed pill as soon as noticed, then continue normally. Beyond 12 hours, take the missed pill, continue the pack, use a condom for 7 days, and consider emergency contraception if unprotected intercourse occurred in the days preceding the missed dose. For the levonorgestrel progestin-only pill, the critical threshold is 3 hours.

04The IUD: an underused contraception#

The intrauterine device (IUD), commonly called coil, is probably the contraceptive method most underused relative to its benefit/risk ratio in Morocco as in many countries. This underuse stems from several misconceptions that should be deconstructed.

The copper IUD is a small plastic device coated with copper wire, placed in the uterus by a gynaecologist during a 5 to 10 minute consultation. The copper exerts a spermicidal effect and prevents implantation. Its effectiveness is 99.2 to 99.4%, comparable to surgical sterilisation. It offers protection duration of 5 to 10 years depending on models, without any action required from the woman between annual check-ups. It is free within the PNPF framework in all Health Centres in Morocco, placement included. Possible side effects: heavier and sometimes more painful periods during the first cycles, which subside in a few months.

The hormonal IUD (Mirena, Kyleena) locally releases a very low dose progestin (levonorgestrel). Beyond its contraceptive action (99.8% effectiveness), it significantly decreases menstrual flow or even causes amenorrhoea in 20% of users, making it an excellent treatment for heavy periods and for endometriosis or adenomyosis. Its effectiveness duration is 5 to 8 years depending on models. It costs 800 to 1,500 MAD to purchase, plus the placement consultation with a gynaecologist.

A persistent misconception holds that the IUD is reserved for women who have already had children. This is false: WHO, French HAS and the Moroccan Society of Gynaecology-Obstetrics now recommend the IUD as a first-line option including in nulliparous women (women never having given birth), with adapted-size models (mini-IUD). This update of recommendations dates back over 15 years but is not yet integrated by all practitioners.

05The contraceptive implant#

The Nexplanon implant is a small flexible plastic rod about 4 cm long, containing a progestin (etonogestrel) which it progressively releases. It is inserted under the skin of the arm (inner face of the non-dominant arm) during a 10 minute consultation under local anaesthesia, and remains in place 3 years. Its removal, also 5 to 10 minutes, is followed by a rapid return of fertility (most often within the following month).

The contraceptive effectiveness of the implant is the highest of all reversible methods: 99.95%, i.e. less than one pregnancy per 2,000 women per year. It works by blocking ovulation and modifying cervical mucus. It is compatible with breastfeeding, smoking, moderate hypertension. Its main drawback is the frequency of irregular bleeding (spotting) during the first year of use, which can bother some women to the point of requesting early removal. Sold in Morocco as Implanon NXT, it costs 1,338 MAD (public retail price) for 3 years, i.e. less than 40 MAD per month equivalent — an excellent cost/effectiveness ratio.

06Emergency contraception#

Emergency contraception, sometimes called "morning-after pill", is intended to avoid an unwanted pregnancy after unprotected intercourse or contraceptive failure (condom rupture, missed pill). Three options exist in Morocco, with decreasing efficacy windows over time.

Levonorgestrel (in Morocco: Navela, Levo or Aconcept; NorLevo and Postinor are equivalent brands) is effective within the first 72 hours after intercourse, with maximum effectiveness in the first 24 hours (95%) which progressively decreases (58% at 72 hours). It is sold in Moroccan pharmacies for about 60 MAD (public retail price); listed in schedule A, it requires a prescription in principle. It is the most accessible option.

Ulipristal acetate (EllaOne) is effective up to 120 hours (5 days) after intercourse, with higher effectiveness than levonorgestrel in the first 72 hours and particularly between 72 and 120 hours where it remains active. It requires a prescription in Morocco and costs 135.50 MAD (public retail price).

The copper IUD placed as emergency within 5 days after intercourse is the most effective method (over 99%) but requires emergency gynaecological consultation, which limits practical accessibility. Its advantage is simultaneously providing subsequent contraception for 5 to 10 years.

None of these methods protect against subsequent intercourse: regular contraception must be resumed from the next intercourse.

07The free national programme (PNPF)#

The PNPF guarantees free access to a basket of contraceptive methods across all Urban Health Centres (CSU) and Rural Health Centres (CSR) of the Ministry of Health. This basket includes the reference combined and progestin-only pills, copper IUDs with placement, male condoms, Depo-Provera quarterly injection (DMPA, medroxyprogesterone), and the initial assessment gynaecological consultation. To benefit from these free services, simply go to a CSU/CSR with your national ID; no particular affiliation is required. The PNPF also receives funding and technical support from UNFPA and WHO, which guarantees the quality and regular availability of products.

For methods not included in the PNPF (hormonal IUD, vaginal ring, patch, and the implant where the programme does not yet offer it, since it was only introduced in 2013 and is being extended), one must turn to the private sector with variable costs depending on brands and regions. CNOPS is not a complementary mutuelle: together with CNSS it manages basic compulsory health insurance (AMO), which generally does not reimburse contraceptives (Mirena, for example, is classed as non-reimbursable). Check with your complementary mutuelle or private insurer.